CTOs on the Move

Relay Technology Management

www.relaytm.com

 
Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.relaytm.com
  • 1 Cambridge Ctr Suite 600
    Cambridge, MA USA '02142
  • Phone: 877.207.3529

Executives

Name Title Contact Details

Similar Companies

Delaware BioScience Association

Delaware BioScience Association has a broad-based membership including pharmaceutical, biotechnology, medical devices, analytical equipment and agricultural products; as well as representatives from academia, medical research, workforce training and other supporting organizations (financial, legal, marketing, consulting, engineering and construction, etc.) that serve the bioscience community. Delaware Bio is focused on being a unified voice for Delaware and the region`s bioscience community to accelerate the growth of human, animal, plant, and industrial biosciences.

PharmaForm

PharmaForm is a leading specialty contract development and manufacturing organization focusing on oral and transmucosal dosage forms. Founded in 1996, PharmaForm has built a reputation for delivering novel and innovative solutions to challenging problems

BionorImmuno

BionorImmuno is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MOMA Therapeutics

We`re on a mission to unlock molecular machines by understanding and respecting their complexities. We`ll be working incredibly hard to discover their untapped potential because we believe they are the key to delivering the next generation of precision medicines.

XyloCor

XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.